Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00390884 · ClinicalTrials.gov registry record · Phase 4
Safety and Immunogenicity of Fluzone® Vaccine in Children Who Received 2 Doses of the 2005-2006 Fluzone Formulation.
A Phase 4 study, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 173
- Enrollment target
NCT00390884: Completed Phase 4 study, sponsored by Sanofi Pasteur, a Sanofi Company.
NCT00390884 is a Phase 4 study that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 173 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00390884, a Phase 4 study, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 173 participants
- Enrollment target
Study Summary
To compare the groups with respect to influenza immune responses following Dose 1 of Fluzone vaccine (2006-2007 formulation).
Primary Outcome
Seroprotection was defined as a Post-vaccination Hemagglutination Inhibition titer of greater than or equal to 1:40.
Interventions
- BIOLOGICAL Influenza Virus Vaccine, Fluzone®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173 participants |
| Start Date | 2006-10 |
| Est. Completion | 2008-09 |
| Phase | Phase 4 |
What the finished NCT00390884 record still lists
NCT00390884 is an interventional study that assigns participants to a tested intervention. The registered 173 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 1 intervention - of which Influenza Virus Vaccine, Fluzone® is the first listed.
NCT00390884 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00390884 about?
NCT00390884 is a clinical study titled "Safety and Immunogenicity of Fluzone® Vaccine in Children Who Received 2 Doses of the 2005-2006 Fluzone Formulation.". To compare the groups with respect to influenza immune responses following Dose 1 of Fluzone vaccine (2006-2007 formulation).
What is the current status of trial NCT00390884?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 173 participants. The study started on 2006-10. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00390884?
The interventions under investigation include: Influenza Virus Vaccine, Fluzone® (BIOLOGICAL).
Who is sponsoring clinical trial NCT00390884?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00390884's enrollment target sits among peer trials
173 481st of 2000 higher than 1,520 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05568719 · 173 participants · Phase 3
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
- NCT07070115 · 173 participants · NA
Evaluating Clinical Hiatal Hernia Outcomes Using OviTex®
- NCT07150832 · 173 participants · NA
Efficacy of the I-CARE Digital Health Intervention
- NCT01000259 · 174 participants
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia